← All Cumberland Pharmaceuticals INC filings

Cumberland Pharmaceuticals INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
CPIX
Cumberland Pharmaceuticals INC
SCHEDULE: Cumberland Pharma CEO Boosts Stake to 38.07%
Cumberland Pharmaceuticals Inc. CEO A.J. Kazimi has reported beneficial ownership of 38.07% of the company's common stock.
NASDAQ
CPIX
Cumberland Pharmaceuticals INC
SCHEDULE: Millennium Management Discloses 4.0% Stake in Cumberland Pharma
Millennium Management and affiliated entities reported a 4.0% passive beneficial ownership stake in Cumberland Pharmaceuticals Inc. as of September 30, 2025.
NASDAQ
CPIX
Cumberland Pharmaceuticals INC
SCHEDULE 13G: Ikarian Capital Discloses 4.9% Passive Stake in Cumberland Pharmaceuticals
Ikarian Capital, LLC and Neil Shahrestani have jointly filed a Schedule 13G, reporting a passive beneficial ownership of 4.9% of Cumberland Pharmaceuticals Inc.'s common stock.
NASDAQ
CPIX
Cumberland Pharmaceuticals INC
SCHEDULE 13G/A: Millennium Management Entities Disclose 5.8% Stake in Cumberland Pharmaceuticals
Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly disclosed a beneficial ownership of 5.8% in Cumberland Pharmaceuticals Inc.
NASDAQ
CPIX
Cumberland Pharmaceuticals INC
SCHEDULE 13G: Cumberland Pharmaceuticals CEO Discloses Significant 40.8% Stake
A.J. Kazimi, CEO of Cumberland Pharmaceuticals Inc., has disclosed beneficial ownership of 40.8% of the company's common stock.
NASDAQ
CPIX
Cumberland Pharmaceuticals INC
SCHEDULE 13G: Millennium Management and Affiliates Disclose 8.8% Passive Stake in Cumberland Pharmaceuticals
Millennium Management LLC, along with its affiliates Integrated Core Strategies (US) LLC, Millennium Group Management LLC, and Israel A. Englander, have disclosed a passive beneficial ownership of 8.8% in Cumberland Pharmaceuticals Inc.